GET INVOLVED

Send a Letter

Time Still Matters for Canadians Living with Pulmonary Arterial Hypertension

Sotatercept was approved by Health Canada in 2024, and the pan-Canadian Pharmaceutical Alliance has successfully negotiated a price for it. Now for the final step: it’s up to the public drug plans to make sotatercept available to patients in need. We need each province to add sotatercept to their public drug program – now.

These provinces and territories haven’t yet added sotatercept to their public drug programs. Send a letter and let your provincial officials know that Time Matters!

PEI

These provinces have already added sotatercept to their public drug programs. Send a letter to say thank you!

Visit our advocacy page